TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.4 YEARS CONSIDERED FOR THE STUDY 16
1.5 CURRENCY 17
1.6 LIMITATIONS 17
1.7 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.2 MARKET RANKING 20
2.2.1 SECONDARY DATA 20
2.2.1.1 Secondary sources 20
2.2.2 PRIMARY DATA 21
2.2.2.1 Key data from Primary sources 21
2.2.2.2 Key industry insights 22
2.3 MARKET SIZE ESTIMATION 23
2.3.1 BOTTOM-UP APPROACH 23
2.3.2 TOP-DOWN APPROACH 24
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 25
2.5 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 31
4.1 ATTRACTIVE OPPORTUNITIES IN THE IN VIVO TOXICOLOGY MARKET 31
4.2 IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE 31
4.3 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT AND BY COUNTRY/REGION 32
4.4 IN VIVO TOXICOLOGY MARKET: DEVELOPING VS. DEVELOPED COUNTRIES 32
4.5 GLOBAL IN VIVO TOXICOLOGY MARKET: GEOGRAPHIC SNAPSHOT 33
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Increasing pharmaceutical R&D activities 35
5.2.1.2 Mandatory government regulations for animal testing 36
5.2.1.3 Innovations in animal models 36
5.2.1.4 Exclusive in vivo toxicology tests 37
5.2.2 RESTRAINTS 38
5.2.2.1 Alternative methods to animal testing 38
5.2.2.2 Disadvantages associated with animal toxicology testing 38
5.2.3 OPPORTUNITIES 39
5.2.3.1 Increasing research in oncology and personalized medicine 39
5.2.3.2 Rising demand for humanized animal models 39
5.2.4 CHALLENGES 40
5.2.4.1 Regulations and laws for the ethical use of animals in research 40
6 IN VIVO TOXICOLOGY MARKET, BY PRODUCT 41
6.1 INTRODUCTION 42
6.2 CONSUMABLES 43
6.2.1 REAGENTS & KITS 44
6.2.2 ANIMAL MODELS 45
6.2.2.1 Mice models 46
6.2.2.2 Rat models 48
6.2.2.3 Other animal models 49
6.3 INSTRUMENTS 51
7 IN VIVO TOXICOLOGY MARKET, BY TESTING TYPE 53
7.1 INTRODUCTION 54
7.2 CHRONIC TOXICITY TESTING 55
7.3 SUB-CHRONIC TOXICITY TESTING 56
7.4 SUB-ACUTE TOXICITY TESTING 57
7.5 ACUTE TOXICITY TESTING 58
8 IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT 60
8.1 INTRODUCTION 61
8.2 IMMUNOTOXICITY 62
8.3 SYSTEMIC TOXICITY 63
8.4 CARCINOGENICITY 64
8.5 GENOTOXICITY 66
8.6 DEVELOPMENTAL AND REPRODUCTIVE TOXICITY (DART) 67
8.7 OTHER TOXICITY ENDPOINTS 68
 
9 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY 70
9.1 INTRODUCTION 71
9.2 OUTSOURCED TESTING FACILITIES 72
9.3 IN-HOUSE TESTING FACILITIES 74
10 IN VIVO TOXICOLOGY MARKET, BY REGION 76
10.1 INTRODUCTION 77
10.2 NORTH AMERICA 78
10.2.1 US 82
10.2.2 CANADA 87
10.3 EUROPE 90
10.3.1 GERMANY 95
10.3.2 UK 98
10.3.3 FRANCE 102
10.3.4 REST OF EUROPE (ROE) 105
10.4 ASIA PACIFIC 110
10.4.1 JAPAN 114
10.4.2 CHINA 118
10.4.3 INDIA 122
10.4.4 REST OF ASIA PACIFIC 126
10.5 LATIN AMERICA 130
10.6 MIDDLE EAST & AFRICA 134
11 COMPETITIVE LANDSCAPE 138
11.1 OVERVIEW 138
11.2 RANKING OF PLAYERS 139
11.3 MARKET SHARE ANALYSIS 140
11.4 COMPETITIVE SCENARIO 142
11.4.1 PRODUCT & SERVICE LAUNCHES 142
11.4.2 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS 142
11.4.3 ACQUISITIONS AND MERGERS 143
11.4.4 EXPANSIONS 143
11.4.5 OTHER DEVELOPMENTS 144
 
12 COMPANY PROFILES 145
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View)*
12.1 THERMO FISHER SCIENTIFIC 145
12.2 DANAHER 150
12.3 CHARLES RIVER LABORATORIES 155
12.4 LABCORP 159
12.5 THE JACKSON LABORATORY 163
12.6 DATA SCIENCES INTERNATIONAL 167
12.7 ENVIGO 169
12.8 EUROFINS SCIENTIFIC 172
12.9 PERKINELMER 176
12.10 SRI INTERNATIONAL 179
12.11 TACONIC BIOSCIENCES 182
12.12 WUXI APPTEC 184
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, Mnm View might not be captured in case of unlisted companies.
13 APPENDIX 187
13.1 INSIGHTS OF INDUSTRY EXPERTS 187
13.2 DISCUSSION GUIDE 188
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 191
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 193
13.5 RELATED REPORTS 195
13.6 AUTHOR DETAILS 196